Recently, phosphorylated tau (p‐tau) in plasma biomarkers have demonstrated high sensitivity and specificity for AD pathologies, and strong performance in distinguishing AD from other neurodegenerative diseases [9, 10, 11, 12, 13, 14]. This evidence concerns the gene MAPT and neurodegenerative disease.